Purpose: The cross talk between tumour cells, myeloid cells, and T cells can play a 27 critical role in tumour pathogenesis and response to immunotherapies. Although the 28 aetiology of mesothelioma is well understood the impact of mesothelioma tumour cells 29 on the surrounding immune microenvironment is less well studied. In this study the effect 30 of the mesothelioma tumour microenvironment on circulating and infiltrating 31 granulocytes and T cells is investigated.
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Conclusions: Our study presents the mechanism behind the cross-talk between 49 mesothelioma tumours and the immune micro-environment and indicates that targeting 50 GM-CSF could be a novel treatment strategy to augment immunotherapy in patients with 51 mesothelioma. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158 /1078 6 Introduction 60 Malignant mesothelioma is an aggressive cancer arising from the mesothelial cells lining 61 the pleura, peritoneum and pericardium (1). The majority of patients present with 62 advanced stage disease and are not candidates for surgery. Although chemotherapy 63 improves outcome for these patients, the median overall survival is less than 24 months 64 (2). Immunotherapy approaches relying on T cell anti-cancer activity, such as peptide 65 vaccines and CAR T cells, have shown only limited efficacy suggesting that the 66 underlying immune microenvironment may play a role in muting the immune response 67 (3, 4) . 68 Myeloid cells play an important role in the balance of pro-and anti-cancer T cell 69 responses. Murine models of mesothelioma have shown that monocytes, macrophages, 70 and dendritic cells may be modulated by the tumour microenvironment (5-7). However, 71 the functional role of granulocytes and their mechanism of action in human mesothelioma 72 is not well understood. Studies in mesothelioma have suggested the ratio between 73 peripheral blood or intra-tumoural neutrophils and lymphocytes correlates with 74 prognosis, indicating a key interaction between these cells in tumour pathogenesis (8) . In 75 other cancers, secreted factors within the tumour microenvironment control the 76 differentiation of granulocytes. In turn this may promote inflammation within the tumour 77 microenvironment or lead to changes in the interaction with the adaptive immune 78 response. Here we investigate the mechanisms underlying the cross-talk between 79 mesothelioma tumour cells, granulocytes and T cells.
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Materials and Methods
82
Patients and sample collection 83 Heparinized blood samples were obtained from patients with malignant mesothelioma 84 (n=47) who were enrolled in IRB approved protocols at the National Cancer Institute, 85 Bethesda, USA and the University of Birmingham, UK before treatment (Table S1 ). 86 Written informed consent was obtained from all the patients and the study was conducted 87 in accordance with recognized ethical guidelines. Blood from healthy donors was 88 obtained from the NIH Blood Bank (n=30) and at the University of Birmingham, UK 89 (n=18), in heparin tubes. Patients with both histologically confirmed pleural (n=24) and 90 peritoneal (n=9) mesothelioma were included in this study and at the time of enrolment 91 had clinical and/or radiological evidence of disease. A number of patients had received 92 prior treatments including surgery and systemic chemo or immune-therapy (Table S1 ). 9 126 Isolation of granulocytes, T cells, and mesothelioma cells for functional assays 127 The whole blood from healthy donors and patients were processed as described above. 128 We isolated the low density granulocytes from the peripheral blood mononuclear layer 129 and high density granulocytes from the layer of white cells on the red cell pellet, 130 following Lymphoprep centrifugation, by magnetic bead isolation using anti-CD15 131 microbeads (BD Pharmingen) and MACS LS separation columns (Miltenyi Biotech) 132 according to manufacturer's instructions. Cell purity was >98% as confirmed by flow 133 cytometry. Cell populations were similarly isolated from collagenase digested tumours 134 using MACS beads (anti-CD15 for granulocytes and anti-CD14 for monocytes), followed 135 by flow cytometric confirmation of purity. The dose of collagenase selected has 136 previously been established to not affect cell surface marker expression or cell viability.
137
For isolation of autologous T cells and myeloid cells from the whole blood the target 138 populations were enriched first using positive selection with CD45 magnetic beads 139 (Miltenyi Biotech), followed by staining with myeloid antibodies (above) and anti-CD3 140 antibody (Biolegend). Cells were sorted on Astrios (Beckman Coulter) using a 100µm 141 nozzle. DAPI was used as a viability marker to gate out the dead cells. To generate tumour conditioned media (TCM), cell lines or sorted patients' tumour cells 145 were plated (1.5 x 10 6 cells) and cultured for 72 hours. The conditioned media was 146 removed and filtered prior to use. Following lymphoprep isolation high density 10 granulocytes were enriched by CD15 magnetic bead isolation as above, healthy donor 148 granulocytes were plated in R10% in 24 well plates, at concentrations of 1x 10 6 per well.
149
TCM was added as 25% of the total volume as indicated. Granulocytes were harvested 150 following 24 hours of culture, washed twice prior to use in suppression assays.
151
Granulocyte viability was confirmed to be >90% in all cases, by flow cytometry, before 152 further experimentation.
154
Autologous T-cell proliferation assays 155 Sorted CD3 + T cells were labelled with 10µM carboxyfluorescein diacetate succinimidyl 156 ester (CFSE; Life Technologies) and cultured with sorted granulocytes at ratios of 1:0, 157 1:0.5, 1:1 in complete media at 37 o C, 5% CO2 for 4 days in the presence of 1:1 ratio of 158 anti-CD3/ anti-CD28 dynabeads (Invitrogen). Cells were stained with V450 anti-CD4 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158 /1078 200μL R10%. Cells were incubated at 37 o C, 5% CO2 for 4 days and then 1μCi/well 3 H-170 thymidine (Perkin Elmer Life Sciences) was added for 12-16 hours. 3 H-thymidine 171 incorporation was measured using a TopCount reader (Perkin Elmer). The suppressive 172 ability of autologous or conditioned granulocytes was assessed by co-culturing purified 173 cells together with the PBLs. nor-NOHA (0.5mM), L-NMMA (0.5mM), iNAC (10mM;
174
Sigma Aldrich) was added to cells in culture. 25mM HEPES was added to the medium to 
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H2O2 was carried out following 30 minutes of incubation at 37°C using a microplate 191 reader at 560nm. The concentrations of cytokines within conditioned media following culture with T cells, 195 mesothelioma cell lines (1x10 6 /mL) or sorted tumour cells were quantified using a 196 competitive enzyme linked immunoassay according to the manufacturers' instructions.
197
The following molecules were tested GM-CSF (Biolegend), IL-13 (BD Biosciences), IL- monocytes from mesothelioma tumours were sorted and also found to suppress T cell 264 proliferation (p=0.0002) ( Supplementary Fig. 1a ). Therefore the tumour 265 microenvironment is able to locally modulate infiltrating myeloid cells to inhibit T cell 266 proliferation. The effects of mesothelioma tumours on the immune system may be limited to the local 271 tissue microenvironment or could also lead to systemic alteration. To test this we 272 compared T cells from the blood of patients at diagnosis to those from healthy donors, 273 and observed that mesothelioma patients' T cells have a reduced proliferation capacity 274 compared to those in healthy donors ( Fig. 2a ). We have previously identified that Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
16 identified suggesting an alternative mechanism must be responsible ( Supplementary Fig.   279 1b). As we identified immunosuppressive granulocytes infiltrating mesothelioma 280 tumours, we therefore hypothesised the T cell suppression may be due to the presence of 281 these circulating immunosuppressive myeloid cells.
282
To investigate the hypothesis, the frequency of granulocytic and monocytic cells was 283 characterised in the whole blood of healthy donors and mesothelioma patients (n=33) at 284 diagnosis (Table S2 ). There were significant increases in the percentage of HLA-DR- from healthy donors ( Fig. 2d and Supplementary Fig. 1c ).
297
As CD15 + granulocytes are the major population of circulating myeloid cells in 298 mesothelioma patients and shared the same immunophenotype as tumour-infiltrating 299 granulocytes described above, their functional effects on T cells was examined further. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158 /1078 CD4 + and CD8 + T cell proliferation at ratios of 1:1 and1:0.5 (T cells:granulocytes) ( Fig.   302 2e and Supplementary Fig. 1d ) and activation (p=0.0078, Fig. 2f ).
303
Immunosuppressive granulocytes may be methodologically identified in the PBMC layer 304 (classical G-MDSC; low-density) and on the red cell pellet (high-density) following 305 density gradient centrifugation of whole blood. Analysis of separated whole blood 306 identified a significant increase in the frequency of granulocytes within the PBMC layer, 307 however the frequency is extremely low (median <10%) with 90% of the granulocytes 308 lying on the red cell pellet (Figure 3a ). This small population of granulocytes had only a 309 weak ability to suppress T cell proliferation (Fig. 3b ). Only the high-density 310 granulocytes, which had increased frequency in the patients, had suppressive activity 311 ( Figure 3b ). Granulocytes from healthy donors had minimal effects on T cell proliferation 312 ( Fig. 1e and Supplementary Fig. 2a ) or IFN-γ release ( Supplementary Fig. 2b ). Therefore Granulocytes can impair T cell proliferation through a number of mechanisms including 320 arginine depletion, nitric oxide species or reactive oxygen species production, and release 321 of immunosuppressive cytokines (15) (16) (17) (18) (19) . We examined iNOS and Arginase I expression Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158 /1078 differences in expression ( Fig.3c ). The addition of the Arginase or iNOS inhibitors, nor-324 NOHA or L-NMMA respectively, to sorted patients' granulocytes did not rescue T cell 325 proliferation thus excluding these mechanisms. (Fig.3d ). No evidence for 326 immunosuppressive cytokine release from these cells was identified in patient plasma by 327 ELISA (IL-10, IL-1β, IL-4, IL-13 Supplementary 2c). In a mesothelioma murine model 
329
Gating on granulocytes identified that mesothelioma patients' upregulate ROS, compared 330 to healthy controls (p=0.03; Fig. 3e, Supplementary Fig. 2d ). Addition of the ROS 331 inhibitor iNAC, to sorted patients' granulocytes restored both autologous CD4 + and CD8 +
332
T cells proliferation ( Fig. 3f and Supplementary Fig. 2e ) and IFN- release (Fig. 3g ). We 333 confirmed that ROS production was reduced by the addition the inhibitor iNAC 334 (p=0.031, Fig. 3h ). PDL1 is another mechanism that myeloid cells may use to modulate T 335 cells. There was no significant difference in the frequency of CD15+PDL1+ cells in the 336 blood or tumours of patients compared to those from healthy controls (Supplementary 337 Fig. 2f ). Correlating the frequency of PDL1+CD15+ cells with CD3+ frequency revealed 338 no significant correlation in the blood (p=0.4976, r=-0.3214) ( Supplementary Figure 2f) , 339 but there was a significant correlation in the tumour (p=0.0583, r=0.8286)
340
( Supplementary Fig 2g and h) . The findings suggest that in the tumour, granulocyte 341 PDL1 may be a secondary mechanism of modulating T cell numbers inside the tumour 342 microenvironment, but not peripherally. Although it is recognised that mesothelioma tumours release G-CSF, which may 346 contribute to granulocyte expansion and recruitment, the mechanism by which 347 granulocytes are polarised to upregulate ROS production and suppress T cells is unknown 348 (21, 22) . Granulocytes produce reactive oxygen specifies through the activity of NADPH 349 oxidase enzyme (NOX2) expression. Consistent with this we demonstrated NOX2 is 350 expressed in patients' granulocytes and healthy donors (Fig. 4a) . To examine the effect of Supplementary Fig. 3a and 3b ) and release of reactive oxide species (Fig. 4d) . PMA was 356 used as positive control for ROS induction in granulocytes upregulation, confirming the 357 mesothelioma specific mechanism ( Supplementary Fig. 3c ). The mesothelioma-358 conditioned granulocytes showed a strong ability to suppress T cell proliferation ( Figure   359 4e), which could be rescued by the addition of iNAC (Fig. 4f ). LOX-1 has been reported 360 to be a marker for some granulocytic MDSCs (23). Conditioned media led to no change 361 in LOX-1 on healthy donor granulocytes (Supplementary 3d). Therefore mesothelioma 362 cells signal to granulocytes to modulate their function.
363
To identify the nature of the mesothelioma-granulocyte cross-talk, mesothelioma 364 conditioned supernatant was first boiled to denature all proteins. Boiled supernatant lost 365 the ability to polarise granulocytes to suppress T cell proliferation (Supplementary Figure   366 3e) consistent with the release of a soluble molecule from the mesothelioma cells.
367
Arginine depletion, a potential mechanism of polarisation due to mesothelioma arginine 
370
ELISAs for cytokines involved in granulocyte signalling were performed of supernatants 371 from mesothelioma cell lines and mesothelioma human primary tumour cells, identified a 372 number of key molecules were highly expressed -G-CSF, GM-CSF, IL-13, IL-6, IL-8, 373 VEGF, PGE2, Mesothelin, (Fig. 5a ). In particular mesothelioma cells release IL-8 374 (neutrophil chemotactic protein; mean concentration 981pg/ml) and G-CSF (mean 375 concentration 283pg/ml) which are known to attract granulocytes into the tumour 376 microenvironment. No evidence of serum amyloid-A release from mesothelioma cells 377 was found. Interrogation of the R2 database confirmed a similar cytokine expression 378 profile from 87 human tumours (Fig. 5b) . Culture of healthy-donor granulocytes with 379 individual recombinant cytokines identified above, showed that GM-CSF led to the 380 highest upregulation of ROS production ( Fig. 5c ) with associated upregulation in NOX2 381 expression ( Supplementary Fig. 3g ). Granulocytes treated with recombinant GM-CSF 382 inhibited T cell proliferation ( Fig. 5d and 5e ), and T cell proliferation was rescued by the 383 inhibitor (iNAC) or removal of reactive oxygen species with catalase ( Fig. 5e ). No 384 increases in plasma GM-CSF concentrations are identified in patients at diagnosis, 385 suggesting that the intra-tumoural release of GM-CSF drives the ROS upregulation in 386 granulocytes. ( Supplementary Fig. 4a ) Addition of anti-GM-CSF neutralising antibody to 387 mesothelioma cell line co-cultures inhibited ROS upregulation ( Fig. 6a and 6b ) and the cell proliferation, confirming the mechanism of mesothelioma polarisation of 392 granulocytes (Fig. 6c ).
393
ROS production from conditioned healthy granulocytes correlated with the concentration 394 of GM-CSF in tumour conditioned media (r=0.438, p=0.0118) (Fig. 6d ).
395
Immunohistochemistry of mesothelioma tumours confirmed that GM-CSF is expressed 396 within the tumour microenvironment of patients ( Fig. 6e and Supplementary Fig. 4c ) and 397 transcriptomic analysis of 87 primary tumour samples within the R2: database 398 demonstrated that GM-CSF is expressed in over 50 % of the samples, and does not 399 correlate with histological subtype (Fig. 6f ).
400
In summary mesothelioma creates an immunosuppressive microenvironment locally and 401 systemically through the release of GM-CSF from tumour cells which induces 402 granulocyte ROS production to inhibit T cell function. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158 /1078 22 infiltrating immune cells, with relatively fewer T cells. To date granulocyte function in 414 mesotheliomas has almost exclusively been studied in murine cell line xenografts.
415
Murine granulocytes may be alternatively activated in mesotheliomas (N1 vs N2) or 416 characterised as granulocytic MDSCs (G-MDSC) (13, 20, 25) . In all of these murine 417 cases the granulocytic cells express reactive oxide speciesa well-established 418 mechanism of T cell suppression (26). We carefully considered whether our tumour-419 infiltrating and circulating granulocytes could be G-MDSC according to recent guidelines 420 for nomenclature which define MDSCs based on immunophenotype, density, and 421 suppressive activity (27). In our mesothelioma patients both circulating and tumour-422 associated granulocytes were CD11b + CD14 -CD15 + / CD66b + , fitting with the G-MDSC 423 phenotype. However blood G-MDSCs are classically described as being low density 424 cells, following separation with density centrifugation. We showed that in mesothelioma 425 patients' blood, low density granulocytes are a minority population within the PBMC 426 layer and have minimal T cell suppressive activitythus the two populations are distinct.
427
In addition no evidence of altered LOX-1 expression, a marker recently identified on low 428 density G-MDSCs, was found after mesothelioma conditioning of healthy donor 429 granulocytes (23). The most suppressive granulocytes are those of high density, and act 430 through ROS release. The intra-tumoural granulocytes we studied share the same 431 immunophenotype and suppressive mechanism. As discussed in the consensus 432 recommendations based on current technology there is no unique marker to distinguish 433 suppressive granulocytes from G-MDSC, particularly for intra-tumoural cells. Notably 434 the need to use cell density on separation as a method to define immune cell subsets is 435 extremely limited, and alternative methodologies will be developed for the future driven through the release of tumour derived factors (15, 28) . Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 30, 2018; DOI: 10.1158 /1078 Inhibition of NOX2 activity with iNAC reversed the suppressive effect of granulocytes 729 on CD4 and CD8 T cell proliferation. g) Inhibition of NOX2 activity with iNAC restored 730 T cell activation, as measured by IFN- release into cell supernatants. h) Culture of 731 patients' granulocytes with iNAC reduced the intracellular production of ROS confirming 732 the known specificity of drug action. 
